Else Nutrition Successfully Completes First Production Trial Run of its Novel, Plant-Based Infant Formula
13 Octubre 2021 - 6:00AM
ELSE NUTRITION HOLDINGS INC.
(BABY.V)
(BABYF)
(0YL.F) ("Else" or the
"Company") the Plant-Based baby, toddler and
children nutrition company, today announced that is has
successfully completed its first commercial trial run of its
patented, Plant-Based Infant Formula for age 0 -12 months as the
Company continues its path for regulatory approval.
The trial run, which took place this week in the
U.S., leveraged a global, first-of-its kind technological
development with one of the raw ingredients in the Plant-Based
formulation. This patented processing method results in a cleaner
ingredient, while keeping the nutritional value fully intact.
“This successful trial is a major step for the
Company, as we move forward to provide real choice when it comes to
dairy-free infant formula,” said Hamutal Yitzhak, CEO &
Co-Founder of Else Nutrition. “The $90 billion global infant
formula market has been dominated by dairy and soy for too long.
This development brings us one step closer to commercializing a
minimally processed, Plant-Based option to millions of wanting
families globally,” she added.
About Else Nutrition Holdings Inc.
Else Nutrition GH Ltd. is an Israel-based food
and nutrition company focused on developing innovative, clean and
plant-based food and nutrition products for infants, toddlers,
children, and adults. Its revolutionary, plant-based, non-soy,
formula is a clean-ingredient alternative to dairy-based formula.
Else Nutrition (formerly INDI) won the "2017 Best Health and Diet
Solutions" award at the Global Food Innovation Summit in Milan.
Else Plant-Based Complete Nutrition for Toddlers was recently
ranked as the #1 Top seller in the baby and toddler formula
category on Amazon. The holding company, Else Nutrition Holdings
Inc., is a publicly traded company, listed as TSX Venture Exchange
under the trading symbol BABY and is quoted on the US OTC Markets
QX board under the trading symbol BABYF and on the Frankfurt
Exchange under the symbol 0YL. Else's Executives include
leaders hailing from leading infant nutrition companies. Many
of Else advisory board members had past executive roles in
companies such as Mead Johnson, Abbott Nutrition, Plum Organics and
leading infant nutrition Societies, and some of them
currently serve in different roles in leading medical centers and
academic institutes such as Boston Children's Hospital, Pediatrics
at Harvard Medical School, USA, Tel Aviv University, Schneider
Children's Medical Center of Israel, Rambam Medical Center and
Technion, Israel and University Hospital Brussels, Belgium.
For more information,
visit: elsenutrition.com or @elsenutrition on Facebook
and Instagram.
Media ContactCallie RappBrilliant
PRCallier@brilliantprm.com
For more information, contact:Mrs. Hamutal
Yitzhak, CEO, Co-Founder & DirectorELSE Nutrition Holdings
Inc.E: hamutaly@elsenutrition.comP: +972(0)3-6445095
Mr. Sokhie Puar, Lead Director of Else
NutritionEmail: sokhiep@elsenutrition.comP : 604-603-7787
US Investor Relations ContactLytham Partners,
LLCMr. Ben ShamsianNew York | PhoenixEmail:
shamsian@lythampartners.comP : 646-829-9701
TSX Venture Exchange
Neither the TSX Venture Exchange nor its
regulation services provider (as that term is defined in the
policies of the TSX Venture Exchange) accepts responsibility for
the adequacy or accuracy of this release.
Caution Regarding Forward-Looking
Statements
This press release contains statements that may
constitute “forward-looking statements” within the meaning of
applicable securities legislation. Forward-looking statements are
typically identified by words such as “will” or similar
expressions. Forward-looking statements in this press release
include statements with respect to the anticipated dates for filing
the Company’s financial disclosure documents. Such
forward-looking statements reflect current estimates, beliefs and
assumptions, which are based on management’s perception of current
conditions and expected future developments, as well as other
factors management believes are appropriate in the circumstances.
No assurance can be given that the foregoing will prove to be
correct. Forward-looking statements made in this press release
assume, among others, the expectation that there will be no
interruptions or supply chain failures as a result of COVID 19 and
that the manufacturing, broker and supply logistic agreement with
the Company do not terminate. Actual results may differ from the
estimates, beliefs and assumptions expressed or implied in the
forward-looking statements. Readers are cautioned not
to place undue reliance on any forward-looking statements, which
reflect management’s expectations only as of the date of this press
release. The Company disclaims any obligation to update or revise
any forward-looking statements, whether as a result of new
information, future events or otherwise, except as required by
law.
Else Nutrition (TSXV:BABY)
Gráfica de Acción Histórica
De Nov 2024 a Dic 2024
Else Nutrition (TSXV:BABY)
Gráfica de Acción Histórica
De Dic 2023 a Dic 2024